Regenerative medicine could potentially cure diseases and may replace palliative treatments for chronic diseases. Stem cells in particular have been studied for their regenerative properties: their potential to repair or replace damaged or diseased human cells or tissues to restore normal function. Studies of stem cell therapies targeting cardiovascular indications such as heart failure (HF), myocardial infarction (MI), cardiomyopathy (CM), and left ventricular dysfunction (LVD) aim to demonstrate that stem cells injected into the circulation or directly into the injured heart tissue improve cardiac function and/or induce the formation of new capillaries.

Components of the report include:

• Overview of CVMD and Stem Cells - epidemiology and regulatory oversight
  
• Pipeline Assessment - regional breakdown, promising late-stage products, early-stage pipeline by molecule type
  
• Clinical Trials Assessment - trial breakdown by phase, leading industry and non-industry sponsors
  
• Market Access - considerations for reimbursement, pricing, and unmet needs
  
• Market Outlook - competitive assessment and key market events (2018–2025) 
  

Cardiovascular Disease
Stem cell development will continue to move towards more prevalent and chronic CV indications

Stem Cells
Type, quantity, integration, and mode of administration of cells are important considerations to maximize therapeutic effect and minimize risks

Market Access
Cost and unmet need will determine reimbursement status in the US